A phase I study of recombinant human arginase I (rhArgI) for patients with advanced hepatocellular carcinoma.

被引：3
|
作者：
Yau, C. C.
Chan, P.
Pang, R.
Chan, W.
Cheng, P. N.
Poon, R.
机构：
[1] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China
[2] 813 Med Ctr Ltd, Hong Kong, Hong Kong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e13503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13503
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I study of pazopanib in patients with advanced hepatocellular carcinoma
    Yau, C. C.
    Chen, P. J.
    Curtis, C. M.
    Murphy, P. S.
    Suttle, A. B.
    Arumugham, T.
    Hodge, J. P.
    Dar, M. M.
    Poon, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics, and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma.
    Yau, Thomas Cheung
    Chang, Paul Ning-Man
    Chan, Pierre
    Pang, Roberta
    Poon, Ronnie Tung Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
    Shahda, Safi
    Loehrer, Patrick J.
    Clark, Romnee S.
    Spittler, A. John
    Althouse, Sandra K.
    Chiorean, E. Gabriella
    ONCOLOGIST, 2016, 21 (06): : 664 - 665
  • [4] Phase I study of irinotecan followed by capecitabine in patients with advanced breast carcinoma.
    O'Connor, T
    Rustum, Y
    Levine, E
    Kepner, J
    Creaven, P
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S70 - S71
  • [5] Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma
    Shiah, Her-Shyong
    Chao, Yee
    Chen, Li-Tzong
    Yao, Tzy-Jyun
    Huang, Jin-Ding
    Chang, Jang-Yang
    Chen, Pei-Jer
    Chuang, Tsai-Rong
    Chin, Yung-Hsin
    Whang-Peng, Jacqueline
    Liu, Tsang-Wu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (05) : 654 - 664
  • [6] A phase I study of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Yopp, Adam
    Arriega, Yuii
    Singal, Amit
    Mansour, John
    Bach, Glen
    Thorpe, Phillip
    CANCER RESEARCH, 2012, 72
  • [7] Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma
    Her-Shyong Shiah
    Yee Chao
    Li-Tzong Chen
    Tzy-Jyun Yao
    Jin-Ding Huang
    Jang-Yang Chang
    Pei-Jer Chen
    Tsai-Rong Chuang
    Yung-Hsin Chin
    Jacqueline Whang-Peng
    Tsang-Wu Liu
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 654 - 664
  • [8] Phase I/II study of everolimus in patients with advanced hepatocellular carcinoma (HCC)
    Blaszkowsky, L. S.
    Abrams, T. A.
    Miksad, R. A.
    Zheng, H.
    Meyerhardt, J. A.
    Schrag, D.
    Kwak, E. L.
    Fuchs, C.
    Ryan, D. P.
    Zhu, A. X.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] A phase I/II study of nivolumab and axitinib in patients with advanced renal cell carcinoma.
    Zibelman, Matthew R.
    Carducci, Michael Anthony
    Ged, Yasser
    Molina, Ana M.
    Ravilla, Rahul
    Shaffer, David R.
    Lambert, Courtney
    Tafseer, Mahvish
    Basiura, Rachel
    Weismann, Danielle
    Kokate, Rutika
    Devarajan, Karthik
    Ruth, Karen
    Alpaugh, R. Katherine
    Anari, Fern
    Ghatalia, Pooja
    Geynisman, Daniel M.
    Plimack, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [10] A multicenter phase II study of donafenib in patients with advanced hepatocellular carcinoma.
    Bi, Feng
    Qiu, Meng
    Chai, Xiaoli
    Niu, Junqi
    Ding, Yanhua
    Bai, Yuxian
    Wu, Lihua
    Shentu, Jianzhong
    Hao, Ping
    Chen, Jinfei
    Li, Qiu
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345